Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce the addition of Holden Hodgson as Senior Managing Director, Derivatives. Mr. Hodgson will be based in the ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...

Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), retaining the price target ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

On Monday, Cardinal Health Inc (CAH) stock saw a modest uptick, ending the day at $120.03 which represents a slight increase of $1.25 or 1.05% from the prior close of $118.78. The stock opened at $118 ...

Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced ...

On Monday, Fulcrum Therapeutics Inc (FULC) stock saw a modest uptick, ending the day at $3.03 which represents a slight increase of $0.02 or 0.66% from the prior close of $3.01. The stock opened at $3 ...

WHQR took an in-depth look at campaign finance, analyzing top fundraisers — and the people and industries who donated to ...

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...